Advasure

RSS

Adjuvanted vaccine against classical swine fever

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Advasure has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 17/03/2008

Authorisation details

Product details
Name
Advasure
Agency product number
EMEA/V/C/000053
Active substance
E2 glycoprotein of classical swine fever virus
International non-proprietary name (INN) or common name
Adjuvanted vaccine against classical swine fever
Species
Pigs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI09AA06
Publication details
Marketing-authorisation holder
Pfizer Limited
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
02/02/2001
Contact address
Ramsgate Road
Sandwich
Kent
CT13 9NJ
United Kingdom

Product information

06/02/2008 Advasure - EMEA/V/C/000053 -

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for suidae

Therapeutic indication

Active immunisation of pigs, over the age of 2 weeks, against Classical Swine Fever (CSF), to prevent
mortality, reduce clinical signs of the disease and the excretion of field virus.
The onset of protection is 2 weeks.
The duration of protection is 6 months.

Assessment history

How useful was this page?

Add your rating